The short answer: Long COVID is one of the most actively studied new HBOT applications, and the early evidence is genuinely encouraging. A randomized, sham-controlled, double-blind trial found that hyperbaric oxygen improved cognition, energy, sleep, and pain in post-COVID patients, with brain imaging showing improved perfusion and neuroplasticity. The strongest results come from a full course of around 40 sessions, and HBOT is best framed as a promising adjunctive recovery tool rather than a cure.
Long COVID is one of the rare areas where a brand-new condition and a decades-old therapy met in real time. When millions of people were left with lingering fatigue, brain fog, sleep disruption, and pain months after their infection cleared, researchers went looking for interventions that could plausibly address the underlying biology. Hyperbaric oxygen therapy became one of the most seriously studied candidates, and unlike a lot of wellness chatter, that interest produced actual randomized trials.
That is what makes this such a strong topic to write about. The mechanism is coherent: much of long COVID appears to involve impaired oxygen use, neuroinflammation, and microvascular and brain-tissue changes, and HBOT acts directly on oxygen delivery and tissue repair. And the evidence is not just mechanistic hand-waving. There is a controlled trial, brain imaging, follow-up data, and newer registries all pointing in a hopeful direction. It still has to be discussed responsibly, because long COVID is a medical condition and the therapy is still considered investigational for it, but the foundation here is real.
Disclosure: Superhuman Chambers sells commercial hyperbaric chambers for wellness businesses. This article is educational only and does not provide medical advice. Long COVID is a medical condition, care should be physician-supervised, and operators are responsible for claims, screening, protocols, and regulatory compliance in their jurisdiction.
Why long COVID became a serious HBOT research target
The biology lines up with what HBOT does
Long COVID, or post-COVID condition, is not one tidy problem. It is a cluster of persisting symptoms — fatigue, cognitive impairment or “brain fog,” sleep problems, pain, and mood changes — that continue for months after the initial infection. Researchers have linked these symptoms to a mix of factors including neuroinflammation, microvascular dysfunction, hypercoagulability, and changes in brain tissue and perfusion. Notably, some clinicians have proposed that long COVID fatigue may partly reflect tissues struggling to extract and use oxygen efficiently.
That is precisely the kind of problem HBOT is built to act on. By raising the amount of oxygen dissolved in the blood under pressure, hyperbaric therapy can push oxygen into tissues that ordinary circulation is struggling to supply, while also influencing inflammation, blood-vessel formation, and stem-cell activity. So the interest in HBOT for long COVID was never a marketing invention. It came from a reasonable match between the suspected mechanisms of the condition and the known effects of the therapy.
Evidence snapshot
The long COVID literature is young but unusually well-structured for a new application, with a controlled trial at its center rather than only anecdotes. The table below separates the key sources by type so you can see why the category looks promising.
| Study | Type | Protocol summary | Main takeaway |
|---|---|---|---|
| Zilberman-Itskovich et al., 2022 (Scientific Reports) | Randomized, sham-controlled, double-blind RCT, 73 patients | 40 daily sessions | Significant gains in cognition, energy, sleep, psychiatric symptoms, and pain; improved brain perfusion and microstructure |
| Karolinska Phase II trial (NCT04842448, ClinicalTrials.gov) | Randomized, placebo-controlled, double-blind, 80 patients | Course of HBOT vs sham | Completed academic trial using quality-of-life (RAND-36) as the primary outcome |
| European prospective registry, 2025 (Scientific Reports) | Real-world registry, patient-reported outcomes | Standard HBOT courses | 56–63% had a clinically relevant improvement at 3 months; cognitive symptoms improved most |
What the clinical research actually shows
The randomized, sham-controlled trial is the anchor
The study that grounds this entire category is a 2022 randomized controlled trial published in Scientific Reports by Zilberman-Itskovich and colleagues. It is well designed for a new application: randomized, sham-controlled, and double-blind, with 73 post-COVID patients who had ongoing symptoms for at least three months. Thirty-seven received a course of 40 daily HBOT sessions and thirty-six received a sham protocol, so neither patients nor evaluators knew who got the real treatment.
The results were broad and statistically meaningful. Compared with sham, HBOT produced significant improvements in global cognitive function, attention, and executive function, along with gains in energy, sleep, psychiatric symptoms, and pain interference. These are exactly the domains that define long COVID, and the fact that the improvements held up against a sham control is what separates this from an open-label feel-good study. The effect sizes were moderate to strong across several of these measures, which is notable in a population that is often difficult to help.
Brain imaging supports the symptom changes
As with the stroke research, the long COVID trial is more convincing because the imaging agrees with the symptoms. The same study reported that the clinical improvements were associated with measurable changes on brain MRI: improved perfusion (blood flow) and microstructural changes in regions tied to cognitive and emotional function. In other words, patients did not just report feeling sharper and more energetic; there were corresponding changes in how their brains were supplied and structured. The authors framed this as HBOT inducing neuroplasticity, the same underlying theme that runs through the most credible hyperbaric brain research.
Follow-up and newer data keep the signal alive
One common worry with any recovery intervention is whether benefits last. Here, a Tel Aviv University follow-up reported that improvements persisted about a year after treatment, which is reassuring for a condition that can otherwise drag on indefinitely. The research base has also continued to grow: a 2025 prospective registry in Scientific Reports tracking real-world long COVID patients found that 56–63% had a clinically relevant improvement in quality-of-life scores three months after HBOT, with cognitive symptoms among the most improved.
That registry is also a good model for honest communication. It noted that a minority of patients did not improve or even reported worsening, which is a reminder that response varies between individuals and that monitoring matters. Meanwhile, an academic Phase II trial run by Karolinska University Hospital — randomized, placebo-controlled, and double-blind — has completed, reflecting how seriously major medical institutions are treating this question. The picture across these sources is consistent: promising, increasingly well-documented, and still being refined.
What independent clinicians say
It is worth noting that this is not only a story told by the chamber industry. Yale Medicine has covered HBOT for long COVID and pointed to the same randomized trial and follow-up data, with physicians describing it as a promising and strong potential adjunctive treatment. They also note the honest caveats: it remains investigational and uninsured for this use, there is no universally standardized dosing yet, and long COVID’s variability makes it hard to predict who benefits most. That balanced framing from an academic medical center is exactly the tone responsible operators should echo.
Protocol and patient selection matter
A course, not a single session
Every meaningful long COVID result comes from a full course of treatment, not a one-off. The anchor trial used 40 daily sessions, and the registries describe multi-week courses as well. The practical takeaway is the same as in other serious HBOT applications: this is a program, and it should be presented as one. That also means chamber capability is part of the story, since a system that delivers consistent, clinical-grade pressure supports the kind of protocol the research is built on. Operators who shop hyperbaric chambers for a long COVID program should prioritize that consistent, clinical-grade pressure over price alone. Our guide to HBOT pressure levels explains why the pressure tier matters when interpreting these studies.
Investigational, physician-supervised, individually screened
The most important framing point is that HBOT for long COVID is still investigational. The evidence is encouraging, but it is not the same as an established, approved indication, and care should be coordinated with the patient’s medical team. Because long COVID is so variable, screening and individualized assessment matter, and the same considerations that govern HBOT safety and contraindications apply directly. Responsible operators set this expectation up front rather than implying a guaranteed fix.
How operators should position HBOT for long COVID
Lead with adjunctive recovery support
The evidence supports a confident but bounded message: HBOT is a promising adjunctive tool that may improve cognition, energy, sleep, and pain in post-COVID patients, especially over a full course and alongside other care. It does not support language that promises to cure long COVID. Given how exhausted and skeptical many long COVID patients have become after being dismissed elsewhere, a precise, evidence-anchored message tends to build far more trust than hype. The phrase “strong adjunctive treatment,” used by academic clinicians, is a good model for the tone.
Speak to a motivated, research-literate audience
Long COVID patients are often among the most informed clients a wellness business will meet, because they have spent months searching for answers. They can tell the difference between a real randomized trial and a vague claim. That makes the honest story — a sham-controlled trial, brain imaging, follow-up data, and a frank acknowledgment that response varies — your strongest asset. Pointing them to a quality course of treatment, with clear expectations, respects how they actually make decisions.
Programs and realistic expectations
Because the research is built on multi-session courses, program-based offerings are both the honest and the effective model. Frame the service as a structured recovery program, set expectations about the number of sessions involved, and integrate it with the rest of a person’s recovery rather than selling single drop-ins. Our guide to how many HBOT sessions you need is a useful companion for that conversation, and the first-session expectations guide helps new clients feel prepared.
Final thoughts
Long COVID is one of the clearest examples of HBOT research moving quickly and honestly at the same time. A sham-controlled randomized trial found meaningful improvements across the symptoms that define the condition, brain imaging supported those gains, follow-up suggested they can last, and newer registries and academic trials continue to build the picture. It is still investigational, response varies between individuals, and medical oversight is essential — but the foundation is real and genuinely hopeful.
For operators, that mix of strong early evidence and required humility is a good place to build from. It lets you offer a credible, premium recovery program that a skeptical, well-researched audience can trust. You can explore the chamber, learn more about Superhuman, contact the team, or keep reading about related HBOT recovery topics in our guides to HBOT for stroke recovery, HBOT for inflammation, and HBOT pressure levels.